Company Profile LogoIntra-Cellular Therapies

Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.

Edit IconSuggest an Edit
Pharmaceutical
Neuroscience
Medical
Health Care
Biotechnology
Biopharma

    Unlock insights on Intra-Cellular Therapies and 2M+ companies now!

    About Intra-Cellular Therapies

    Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (D

    Company Highlights
    Year Founded

    2002

    icon-altEmployees

    625

    Location (HQ)

    USA

    Since Last Funding

    4 months

    Monthly Website Visitors

    21.9K

    icon-altTotal Investment Amt

    $2.3B

    Last Funding Round

    Post Ipo Debt

    icon-altMoM Headcount Growth

    3.65%

    icon-altYoY Headcount Growth

    12.21%

    Key Metrics

    Senior Hires

    NameLinkedin ProfilePositionDate Joined
    John Doehttps://www.linkedin.com/in/johndoeCEOCEO
    Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
    John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
    Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
    Get API access to complete private company database with growth metrics from 15 sources

    Similar Companies

    Health Care

    Medical

    Biotechnology

    Biopharma

    Pharmaceutical

    Pharmaceutical Manufacturing

    Pharmaceuticals

    Neuroscience